MARKET

XRTX

XRTX

Xortx Therapeutics Inc
NASDAQ
1.020
-0.170
-14.28%
After Hours: 1.080 +0.06 +5.87% 19:15 10/04 EDT
OPEN
0.9252
PREV CLOSE
1.190
HIGH
1.180
LOW
0.9110
VOLUME
279.69K
TURNOVER
0
52 WEEK HIGH
6.12
52 WEEK LOW
0.8953
MARKET CAP
13.25M
P/E (TTM)
-2.4451
1D
5D
1M
3M
1Y
5Y
XORTX Therapeutics prices $5M underwritten public offering
Clinical pharmaceutical company XORTX Therapeutics (XRTX) priced a $5M underwritten public offering...
Seekingalpha · 13h ago
Inhibrx, Immunovant top healthcare gainers; Biohaven, KalVista lead losers' pack
Gainers: Inhibrx (INBX) +27%. Immunovant IMVT +26%</fo...
Seekingalpha · 15h ago
XORTX Announces $5M Public Offering
XORTX Therapeutics Inc. (&#34;XORTX&#34; or the “Company”) (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat
Benzinga · 17h ago
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.
Benzinga · 09/26 07:43
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day extension to March 13, 2023 to regain compliance.
Benzinga · 09/23 16:16
BRIEF-Xortx Completes Positive Pre-Phase 3 Meeting With U.S. FDA
BRIEF-Xortx Completes Positive Pre-Phase 3 Meeting With U.S. FDA
Reuters · 09/19 11:17
XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration
CALGARY, Alberta, Sept. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical development stage pharmaceutical company focused on developing innovative therapies to treat pr...
GlobeNewswire · 09/19 11:00
XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2022
Hyperuricemia is Associated with Accelerated Polycystic Kidney Disease (“PKD”) InjuryCALGARY, Alberta, Sept. 01, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical...
GlobeNewswire · 09/01 11:00
More
About XRTX
XORTX Therapeutics Inc. is a Canada-based pharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) due to coronavirus infection. Its lead product candidates are XRx-008, XRx-101 and XRx-225. XRx-008 is a late clinical stage program focused on demonstrating the potential of its therapy for ADPKD. XRx-101 is a program to treat acute kidney injury associated with Coronavirus/ COVID-19 infection, AKI and associated health consequences. XRx-225 is a program for the treatment of T2DN. It is also working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.

Webull offers kinds of XORTX Therapeutics Inc stock information, including NASDAQ:XRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XRTX stock methods without spending real money on the virtual paper trading platform.